tbuckley/cabot-search huggingface dataset:
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
Authors: Martine J. Piccart-Gebhart, Andrew Peter Holmes, Jose Baselga, Evandro De Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E. Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D. Gelber, Edith A. Perez
Journal: Journal of Clinical Oncology (2014)

LBA4 Background: Lapatinib (L) is a small molecule tyrosine kinase inhibitor. The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) Trial is a randomised, phase III trial comparing 3 orally L-containing regimens with T alone, each given for 1 year as adjuvant treatment for HER2-positive EBC. Methods: From Jan 2007 to Jul 2011, 8,381 patients (pts) were randomized from 946 participating sites in 44 countries to receive either T alone (N=2097), L alone (N=2100), T→L (N=2091), or T+L (N=2093). Anti-HER2 therapy was initiated after completion of all chemotherapy (Design 1), concomitantly with a taxane following anthracycline (Design 2), or concomitantly with a non-anthracycline, platinum-containing regimen (Design 2B). Dosing in Design 1 was T 8 mg/kg IV loading dose followed by 6 mg/kg IV q3 weeks for 52 weeks; or L 1500 mg/d for 52 weeks; or T 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly for a total of 12 weeks followed by a 6-week treatment-free interval followed by L 1500 mg/d for a total of 34 weeks; or T 8 mg/kg IV loading dose followed by 6 mg/kg IV q3 weeks concomitant with L 1000 mg/d for 52 weeks. In Design 2, 80 mg/m2 weekly paclitaxel or 75 mg/m2 3-weekly docetaxel were administered concomitantly with the anti-HER2 agents. In Design 2B, 6 cycles of docetaxel (75 mg/m2) with carboplatin (AUC 6) were administered concomitantly with the anti-HER2 agents; T was administered weekly and L doses were reduced when combined with chemotherapy. The primary endpoint is disease-free survival (DFS). The L alone arm was closed on August 18, 2011, following Independent Data Monitoring Committee recommendation based on a planned interim analysis showing that L was unlikely to be non-inferior to T alone. Results: The clinical cut-off date for the first planned DFS analysis was December 6, 2013, predicted to obtain a protocol-defined median follow-up of approximately 4.5 years. Conclusions: Data processing is ongoing and analysis will be completed in May 2014. Results for DFS, drug administration and safety will be presented for the first time. Clinical trial information: NCT00490139.
Medicine, Memoir
Authors: Steven Weiss
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Factors and Therapeutic Decisions in Axillary Node-Negative Breast Cancer
Authors: R. Elledge
Journal: Annual Review of Medicine (1993)

The incidence of node-negative breast cancer is increasing, and it is becoming a more commonly encountered clinical problem. Prognostic factors such as tumor size, histopathological characteristics, receptor status, proliferative markers, biochemical alterations, and gene abnormalities can be useful in assessing the risk of cancer recurrence after primary local therapy. By accurately assessing the risk of recurrence, informed decisions can be made about whether or not to treat with adjuvant systemic therapy.
Steroids and acute pyogenic meningitis.
Journal: BMJ (1970)

MEDIBRJouRALoccupational scheme in the country, no matter how small.Much hard bargaining lies ahead if doctors are to get reasonable terms from the N.H.S. superannuation scheme, and a better understanding by the profession of what is entailed will help its negotiators.Pension rights are an in- tegral part of current remuneration.Under a good scheme the sum total of a person's pension rights may be worth the equivalent of nearly 10 years' pay at the age of retirement.It is the biggest single investment many will ever have, and is therefore worthy of the attention that would be given to any other asset of comparable magnitude.
Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation
Authors: Jane L. Liesveld, Gordon L. Phillips, Michael W. Becker, Louis Constine, Jonathan W. Friedberg, Jeffrey Andolina, Laurie Milner, Therese Smudzin, Ollivier Hyrien, Katie L Dawson, Yuhchyau Chen
Journal: Blood (2012)
Ethical issues involved in the growing AIDS crisis. Council on Ethical and Judicial Affairs
Journal: JAMA (1988)

This report was filed by the AMA House of Delegates at its 1987 Interim Meeting. The Council on Ethical and Judicial Affairs states its beliefs that a physician should not refuse to treat a patient solely because the patient is HIV seropositive; that physicians must provide competent medical service with compassion and respect for human dignity; that physicians who are unable to provide the services required by AIDS patients should make referrals; that physicians should respect the privacy rights of AIDS and seropositive patients; that when a seropositive individual is endangering a third party, in the absence of statutory regulation, the physician should try to persuade the individual to cease doing so, notify the authorities if persuasion fails, and notify the endangered party if all else fails; and that a physician who has AIDS or is seropositive should not engage in any activity that creates a risk to patients.
Centrifugal lipodystrophy
Authors: C.B. ZACHARY, R.S. WELLS
Journal: British Journal of Dermatology (1984)

Journal Article Centrifugal lipodystrophy Get access C.B. ZACHARY, C.B. ZACHARY Department of Dermatology, Guy's Hospital, London SE1 Dr C.B.Zachary, Department of Dermatology, Guy's Hospital, London, SE1 9RT. Search for other works by this author on: Oxford Academic Google Scholar R.S. WELLS R.S. WELLS Department of Dermatology, Guy's Hospital, London SE1 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 110, Issue 1, 1 January 1984, Pages 107–110, https://doi.org/10.1111/j.1365-2133.1984.tb07320.x Published: 01 January 1984 Article history Accepted: 02 July 1983 Published: 01 January 1984
Highlights
Journal: JAMA Dermatology (2019)

PUVA at Low Dose and Frequency for Early MF 538Psoralen-UV-A (PUVA) therapy is standard first-line treatment for early mycosis fungoides (MF), but much remains unknown about optimal dosing, duration, or use as maintenance therapy.In this randomized clinical trial of 27 patients with early-stage MF, Vieyra-Garcia et al found that low-dose, low-frequency PUVA therapy appears to be highly effective at achieving disease-free remission, and that its use as maintenance therapy might extend that outcome.Guitart provides an Editorial.
Future therapy of hepatitis C
Authors: John G. McHutchison, Keyur Patel
Journal: Hepatology (2002)

Currently available therapies for the treatment of chronic hepatitis C are effective in half of patients, but are expensive, often poorly tolerated, and unsuitable for certain patients populations. The ideal therapy would be highly effective, orally bioavailable, have minimal side effects, be cost effective, and suitable for the majority of patients with hepatitis C. Recent advances in understanding the replication cycle of hepatitis C virus (HCV) and structural, crystallographic definitions of components of the viral polyprotein have improved the prospects for development of novel therapies. The lack of a small animal model of HCV infection continues to hamper progress in the preclinical evaluation of new antivirals and vaccines. Strategies to enhance response to current therapies include the development of novel interferons and delivery systems, nucleoside analogues that have reduced hemolysis compared with ribavirin, inosine 5′ monophosphate dehydrogenase inhibitors, and other immunomodulators that are being evaluated as adjunctive therapy to interferon-based regimens. Compounds in preclinical or early phase human trials include small molecules that inhibit virus specific enzymes (such as the serine proteases, RNA polymerase and helicase), or those that prevent translation initiation (such as antisense molecules and ribozymes). Antifibrotic agents are also being developed in an attempt to prevent disease progression in patients in whom HCV RNA cannot be eradicated. While the advent of these newer compounds represent an exciting phase in the treatment of HCV, their safety and efficacy need to be established. Most of these newer therapies are unlikely to be available for routine clinical use in the next 3 to 5 years. (Hepatology 2002;36:S245-S242).
Ten speed bicycles and shoulder bags. Hazard to fair faces
Authors: D. W. Furnas
Journal: JAMA (1976)

THE SIMULTANEOUS popularity of the ten-speed bicycle (bicycle sales now outnumber automobile sales in the United States.<sup>1</sup>) and the shoulder bag has introduced yet another hazard into modern life. The forward position of a cyclist on the modern, diamond-frame, ten-speed bicycle adds efficiency to pedaling efforts and cuts down resistance but at the same time gives insecure purchase for the strap of a shoulder bag (Fig 1). A small movement can cause the strap of the bag to slip from the shoulder, slide down the arm to the handlebar, and swing forward in a pendulum movement toward the front wheel (Fig 2). The rotating spokes of the front wheel catch the bag and wedge it solidly between the fork and the wheel. The front wheel stops precipitously, the bicycle turns end-up, and the rider is thrown over the handlebars, often with disastrous results (Fig 3). <h3>Report of Cases</h3><h3>Case</h3>
BRITISH ASSOCIATION OF DERMATOLOGY AND SYPHILOLOGY.
Journal: British Journal of Dermatology (1926)

British Journal of DermatologyVolume 38, Issue 5 p. 212-213 BRITISH ASSOCIATION OF DERMATOLOGY AND SYPHILOLOGY. First published: May 1926 https://doi.org/10.1111/j.1365-2133.1926.tb09993.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume38, Issue5May 1926Pages 212-213 RelatedInformation
Annual Reprint of the Reports of the Council on Pharmacy and Chemistry of the American Medical Association with the Comments That Have Appeared in the Journal of the American Medical Association, 1951.
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Measles--United States, 1983
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Listings
Journal: Annals of Internal Medicine (2002)

Book Listings16 July 2002Book ListingsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-2-200207160-00029 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail CardiologyAlcohol and Heart DiseaseR Watson and AK Myers, eds. 261 pages. Philadelphia: Taylor & Francis; 2002. $80.00. ISBN 0415273471. Order phone 800-821-8312.Beta-Blockers in Heart FailureJ McMurray and MJ Kendall. 108 pages. Philadelphia: Taylor & Francis; 2002. $15.00. ISBN 1853179027. Order phone 800-821-8312.Blackwell's Primary Care Essentials: CardiologyJ Sutherland. 304 pages. Cambridge, MA: Blackwell Science; 2001. $40.00. ISBN 0632044756. Order phone 800-759-6102.Cardiac Arrythmias: Practical Notes on Interpretation and Treatment6th edition. DH Bennett. 340 pages. Boston: Arnold; 2002. $30.00. ISBN 0340807318. Order phone 800-759-6102.Cardiogenic Shock: Diagnosis and TreatmentD Hasdai, PB Berger, A Battler, and DR Holmes Jr, eds. ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 July 2002Volume 137, Issue 2Page: B1 ePublished: 16 July 2002 Issue Published: 16 July 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.Loading ...
Critical (panic) value notification: an established laboratory practice policy (parameter)
Authors: G. D. Lundberg
Journal: JAMA (1990)

A laboratory test begins when a clinician (or patient) asks a question that requires a laboratory result to answer. It ends with an appropriate action being taken on the patient's behalf based on that result. There are at least 11 steps in the performance of that test (Figure). We have called that sequence the "brain-to-brain loop."<sup>1</sup>A chain is known to be only as strong as its weakest link. Thus, anything that interferes with the complete closing of this loop for every laboratory test requested produces at the least, a waste, and at the most, a tragedy. Historically, most laboratory personnel have concentrated on the analytic portion of the loop. However, modern quality assurance requires that laboratory personnel consider all steps, actively participating in preanalytic and postanalytic components. The critical value reporting system is an early example of this expanded approach. Nearly 20 years ago we organized such a
Chronic regional enteritis complicated by a nephrotic syndrome due to amyloidosis. Antemortem clinical study
Authors: L. Wallenstein
Journal: JAMA (1966)

THE ASSOCIATION of amyloidosis and regional enteritis in a significant number of patients was not generally appreciated until Werther et al<sup>1</sup>reported 17 autopsy cases in 1960. Whereas the cases of amyloidosis secondary to ulcerative colitis seem to have a high incidence of periintestinal suppuration and fistulization as preceding factors, this is not the usual pattern in the association with regional enteritis. Whether the amyloidosis associated with regional enteritis is secondary to the granulomatous process itself or to microscopic abscesses and sinus tracts is still debatable. Immunologic and genetic errors of metabolism may yet prove to play a definitive role in both situations. The cases reported in the literature have all been extracted from autopsy material. For the past seven years one of us has been treating a patient with severe regional enteritis in whom the onset of proteinuria, edema, and hypoproteinemia in the past three months suggested the
Emergency Contraception
Authors: David A. Grimes, Elizabeth G. Raymond
Journal: Annals of Internal Medicine (2002)

Emergency contraception is used to prevent pregnancy after a coital act not adequately protected by a regular method of contraception. In contrast to early medical abortion, emergency contraception prevents a pregnancy from starting and does not disrupt an established pregnancy. The most commonly used approaches consist of two oral doses of contraceptive steroids. The levonorgestrel-only regimen (levonorgestrel, 0.75 mg, repeated in 12 hours) appears to be more effective and better tolerated than the Yuzpe regimen (ethinyl estradiol, 100 µg, and levonorgestrel, 0.5 mg, repeated in 12 hours). In the largest randomized, controlled trial to date, levonorgestrel prevented about 85% of pregnancies that would have occurred without its use. Hormonal emergency contraception has no known medical contraindications, although it is not indicated for suspected or confirmed pregnancy. However, if hormonal emergency contraception is inadvertently taken in early pregnancy, neither the woman nor the fetus will be harmed. Nausea and vomiting associated with the Yuzpe regimen can be reduced by prophylactic use of meclizine. A strong medical and legal case exists for making hormonal emergency contraception available over the counter, as has happened in countries other than the United States. Easier access to and wider use of emergency contraception could dramatically lower the high rates of unintended pregnancy and induced abortion in the United States.
Primary sclerosing cholangitis and Hodgkin's disease
Authors: K Man
Journal: Hepatology (1993)

Three patients with primary sclerosing cholangitis and Hodgkin's disease, a previously unrecognized association, are reported. All three patients were men, and one patient had Crohn's disease of the colon. Primary sclerosing cholangitis was diagnosed 2, 11 and 17 yr before diagnosis of Hodgkin's disease in the three patients, and all three had advanced biliary cirrhosis prompting referral for liver transplantation. The symptoms of Hodgkin's disease were often masked by similar manifestations of primary sclerosing cholangitis, particularly symptoms of recurrent biliary sepsis. Hodgkin's disease is another disorder that may occur in patients with primary sclerosing cholangitis, particularly in the setting of advanced disease, and may be masked by the underlying hepatobiliary disease. (HEPATOLOGY 1993;18:1127-1131).
A Systematic Course of Qualitative Chemical Analysis of Inorganic and Organic Substance. With explanatory notes.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sudden infant death syndrome and maternal age: etiologic implications
Authors: D. R. Peterson
Journal: JAMA (1982)

During a 12-year period (1969 through 1980), 431 episodes of sudden infant death syndrome (SIDS) occurred in King County, Washington. Longitudinal analysis of these data confirms the inverse association of SIDS occurrence with maternal age, which has been reported repeatedly from previous cross-sectional analyses. Risk of SIDS increases with increasing birth order, but the inverse maternal age gradient remains constant within each birth-order category. Available evidence suggests that maternal age may be a more important clue to SIDS causation than previously supposed. Assessment of established SIDS risk factors in relation to maternal age deserves further attention. The role of nutrition in pregnancy in relation to maternal age and SIDS risk may also be a productive avenue for future investigation. (<i>JAMA</i>1982;247:2250-2252)
Book Review Preeclamptic and Eclamptic Toxemia of Pregnancy . By Lewis Dexter, M.D., and the late Soma Weiss, M.D. In collaboration with Florence W. Haynes, Herbert S. Sise and James V. Warren. 8°, cloth, 415 pp., with 47 illustrations. Boston: Little, Brown and Company, 1941. $5.00.
Journal: New England Journal of Medicine (1942)
Oblique rib views after blunt chest trauma: an unnecessary routine?
Authors: J Danher, B Eyes, K Kumar
Journal: BMJ (1984)

careful examination showed no burns.He remained without a fever through- out his admission.He was nursed in bed and received benzylpenicillin 500 000 units four times daily for four days and oxygen via a nasal cannula.Chest radiography (figure) showed bilateral patchy consolidation, more noticeable on the left, with mediastinal and right supraclavicular surgical emphysema and no fractures.He made a rapid, uneventful recovery and was discharged home four days later with only a few persisting pulmonary crepitations.As is common in this region, he failed to attend for review.